title: [Predictive factors of response to erytrhocytapheresis in patients with biochemical iron overload with or without hereditary hemochromatosis type 1].
abstract: OBJECTIVE
  Progressive increase of iron stores leads to the development of varied diseases, some of them irreversible. Until now, phlebotomy has been the cornerstone in the treatment of iron overload. Nevertheless, each erytrhocytapheresis procedure removes more than twice the volume of red cells and iron than phlebotomy, allowing to achieve iron depletion in shorter time. Our aim was to describe clinical features and analytical tests parameters of patients with iron overload, to analyze global and subsets results, to suggest predictive factors of response and to evaluate security of the procedure.
  
  
  METHODS
  Descriptive, longitudinal and prospective study of 663 procedures corresponding to 35 patients (December 2002 to October 2011). Response was defined as a serum ferritine value lower than 50 ng/mL during two months. Statistical analysis was done with SPSS(®) v 17.0 and the minimum level of statistical significance was defined as p-value < 0,05.
  
  
  RESULTS
  Seventy-seven percent of patients reached response with 11 (interquartile range 1-42) erytrhocytapheresis procedures and at 11 (1-108) months. Eighty-seven point five percent of patients who did not achieve response had their ferritine values reduced in more than 50%. The decrease of all iron metabolism parameters was statistically significant. Statistically significant predictive factors of response to erytrhocytapheresis were: patients younger than 60 years-old, hereditary hemochromatosis cases, and patients who had received treatment with phlebotomies prior to erytrhocytapheresis.
  
  
  CONCLUSIONS
  Erytrhocytapheresis is a secure and effective procedure for iron depletion in patients with iron overload, especially in high risk hereditary hemochromatosis cases that do not respond to phlebotomies.
authors.affiliation: Servicio de Transfusión, Hospital Universitario Cruces, Baracaldo, Vizcaya, España. Electronic address: ingrid.mps@gmail.com.
authors.forename: Ingrid
authors.initials: I
authors.lastname: Parra Salinas
authors.affiliation: Servicio de Transfusión, Hospital Universitario Miguel Servet, Zaragoza, España.
authors.forename: Anel
authors.initials: A
authors.lastname: Montes Limon
authors.affiliation: Unidad de anemias, Hospital Universitario Miguel Servet, Zaragoza, España.
authors.forename: Valle
authors.initials: V
authors.lastname: Recasens Flores
authors.affiliation: Unidad de coagulación, Hospital Universitario Miguel Servet, Zaragoza, España.
authors.forename: Nuria
authors.initials: N
authors.lastname: Fernandez-Mosteirin
authors.affiliation: Servicio de Transfusión, Hospital San Jorge, Huesca, España.
authors.forename: Jose Antonio
authors.initials: JA
authors.lastname: Garcia-Erce
mesh_terms: D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D001781:Blood Component Removal; D017707:Erythrocyte Transfusion; D005260:Female; D005293:Ferritins / Q000097:blood; D005819:Genetic Markers; D006432:Hemochromatosis / Q000097:blood / Q000235:genetics / Q000628:therapy*; D006801:Humans; D019190:Iron Overload / Q000097:blood / Q000235:genetics / Q000628:therapy; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D005819:Genetic Markers; D005293:Ferritins
keywords: Citaféresis; Cytapheresis; Flebotomía; Hemocromatosis hereditaria; Hereditary hemochromatosis; Iron overload; Phlebotomy; Sobrecarga férrica